Ubs Group Ag Lexaria Bioscience Corp. Transaction History

Ubs Group Ag

$582 Billion
Q4 2025

A detailed history of Ubs Group Ag transactions in Lexaria Bioscience Corp. stock. As of the latest transaction made, Ubs Group Ag holds 361,300 shares of LEXX stock, worth $382,978. This represents 0.0% of its overall portfolio holdings.

Number of Shares

361,300

Previous 7,090 4995.91%

Holding current value

$382,978

Previous $6,000 6266.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2025 Jan 29, 2026	BUY	$0.82 - $1.14 $290,452 - $403,799	354,210 Added 4995.91%	361,300 $382,000
Q3 2025 Nov 13, 2025	BUY	$0.79 - $1.53 $802 - $1,554	1,016 Added 16.73%	7,090 $6,000
Q2 2025 Aug 14, 2025	BUY	$0.85 - $1.69 $5,162 - $10,265	6,074 New	6,074 $5,000
Q4 2024 Feb 14, 2025	BUY	$2.01 - $3.3 $233 - $382	116 New	116 $0
Q4 2023 Feb 09, 2024	BUY	$0.92 - $1.69 $4,169 - $7,659	4,532 New	4,532 $5,000

Q2 2023 Aug 11, 2023	SELL	$0.69 - $2.69 $3,132 - $12,212	-4,540 Reduced 97.87%	99 $0
Q1 2023 May 12, 2023	SELL	$2.47 - $3.47 $2,363 - $3,320	-957 Reduced 17.1%	4,639 $12,000
Q4 2022 Feb 08, 2023	SELL	$1.95 - $2.98 $1,563 - $2,389	-802 Reduced 12.54%	5,596 $13,000
Q3 2022 Nov 10, 2022	BUY	$0.74 - $3.28 $1,647 - $7,304	2,227 Added 53.39%	6,398 $16,000
Q2 2022 Aug 10, 2022	BUY	$1.88 - $4.06 $2,835 - $6,122	1,508 Added 56.63%	4,171 $12,000
Q1 2022 May 16, 2022	SELL	$2.78 - $4.7 $4,089 - $6,913	-1,471 Reduced 35.58%	2,663 $9,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $6.9 $15,998 - $28,524	4,134 New	4,134 $17,000

Others Institutions Holding LEXX

# of Institutions

Shares Held

2.15M

Call Options Held

Put Options Held

View Full List

About Lexaria Bioscience Corp.

Ticker LEXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,951,000
Market Cap $6.31M
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...

More about LEXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account